Onconomics RGCCprovides highly detailed and accurate information about how effective specific anti-cancer drugs and targeted therapies are in treating cancer.
The test combines a molecular and a cellular approach by incorporating two procedures: epigenetic analysis and viability assays. A sample of blood or tissue is analysed to test how effective specific therapies and treatments are at suppressing cancer.
Together, the results of these two testing methods provide scientists and clinicians with a comprehensive breakdown of the most suitable and successful treatments for cancer.
Test details
Sample type
Blood or tissue for Central Nervous System Primary Tumors
Analysis period
Approx. 7 days
Cancer type
Applicable for all cancer types
Final results
7-10 days after sample delivery
Sample size
15-25 ml peripheral whole blood. Tissue sample: Minimum 400mg.
Price*
1750 €
* The prices of the tests may be an issue of local additional taxes and value added taxes which are dependent of each country’s legislation. The prices may vary in areas that are under the jurisdiction of a distributor. These prices are for the tests only, and they do not include in-office fees such as consultation, blood draws, etc.
* RGCC is not liable for any third-party comments or claims regarding our products. For accurate and up-to-date information about our offerings, please refer to our official website: rgcc-international.com
